FDA issues guidance on documenting drug bioavailability, bioequivalence

03/26/2014 | In-PharmaTechnologist.com

The FDA has issued guidance that explains how drugmakers can best meet the agency's bioequivalence and bioavailability requirements for investigational new drug applications and new drug applications. The guidelines include various approaches to documenting the bioavailability of new drugs.

View Full Article in:

In-PharmaTechnologist.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC